Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A 2 Proves Renal Origins of Urinary PGI-M and TX-M
Authors:
- Jane A. MitchellJMJane A. Mitchell
- Rebecca B. KnowlesRKRebecca B. Knowles
- Nicholas S. KirkbyNKNicholas S. Kirkby
- Daniel M. ReedDRDaniel M. Reed
- Matthew L. EdinMEMatthew L. Edin
- William E. WhiteWWWilliam E. White
- Melissa V. ChanMCMelissa V. Chan
- Hilary LonghurstHLHilary Longhurst
- Magdi M. YaqoobMYMagdi M. Yaqoob
- Ginger L. MilneGMGinger L. Milne
- Darryl C. ZeldinDZDarryl C. Zeldin
- Timothy D. WarnerTWTimothy D. Warner
Open Access
- 16 February 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 122 (4) , 555-559
Abstract
Rationale:: The balance between vascular prostacyclin, which is antithrombotic, and platelet thromboxane A 2 , which is prothrombotic, is fundamental to cardiovascular health. Prostacyclin and thromboxane A 2 are formed after the concerted actions of cPLA 2 α (cytosolic phospholipase A 2 ) and COX (cyclooxygenase). Urinary 2,3-dinor-6-keto-PGF 1α (PGI-M) and 11-dehydro-TXB 2 (TX-M) have been taken as biomarkers of prostacyclin and thromboxane A 2 formation within the circulation and used to explain COX biology and patient phenotypes, despite concerns that urinary PGI-M and TX-M originate in the kidney. Objective:: We report data from a remarkable patient carrying an extremely rare genetic mutation in cPLA 2 α, causing almost complete loss of prostacyclin and thromboxane A 2 , who was transplanted with a normal kidney resulting in an experimental scenario of whole-body cPLA 2 α knockout, kidney-specific knockin. By studying this patient, we can determine definitively the contribution of the kidney to the productions of PGI-M and TX-M and test their validity as markers of prostacyclin and thromboxane A 2 in the circulation. Methods and Results:: Metabolites were measured using liquid chromatography-tandem mass spectrometry. Endothelial cells were grown from blood progenitors. Before kidney transplantation, the patient’s endothelial cells and platelets released negligible levels of prostacyclin (measured as 6-keto-prostaglandin F 1α ) and thromboxane A 2 (measured as TXB 2 ), respectively. Likewise, the urinary levels of PGI-M and TX-M were very low. After transplantation and the establishment of normal renal function, the levels of PGI-M and TX-M in the patient’s urine rose to within normal ranges, whereas endothelial production of prostacyclin and platelet production of thromboxane A 2 remained negligible. Conclusions:: These data show that PGI-M and TX-M can be derived exclusively from the kidney without contribution from prostacyclin made by endothelial cells or thromboxane A 2 by platelets in the general circulation. Previous work relying on urinary metabolites of prostacyclin and thromboxane A 2 as markers of whole-body endothelial and platelet function now requires reevaluation.Keywords
This publication has 30 references indexed in Scilit:
- LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 ExpressionPLOS ONE, 2013
- Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cellsBlood, 2013
- Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular systemProceedings of the National Academy of Sciences, 2012
- Involvement of cyclo‐oxygenase‐1‐mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteriesExperimental Physiology, 2011
- Endothelial von Willebrand factor regulates angiogenesisBlood, 2011
- Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivoNephrology Dialysis Transplantation, 2009
- Inherited human cPLA2α deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunctionJournal of Clinical Investigation, 2008
- COX-2 Inhibitors and Cardiovascular RiskJournal of Cardiovascular Pharmacology, 2007
- COX-2 and the KidneyJournal of Cardiovascular Pharmacology, 2006
- Estimated rate of prostacyclin secretion into the circulation of normal man.Journal of Clinical Investigation, 1981